DRUG DEVELOPMENT PIPELINE

Back to the Drug Development Pipeline

Fosfomycin/Tobramycin Inhalation Solution (FTI)

Phase Two

Phase Two

Therapeutic Approach

Anti-Infective

Fosfomycin/tobramycin inhalation solution (FTI) is a combination antibiotic consisting of fosfomycin and tobramycin. FTI has shown increased effectiveness against bacteria compared to fosfomycin or tobramycin alone.

Status

A phase 3 study will begin in 2017 to test the safety and effectiveness of FTI.

Sponsor

This program is sponsored by CURx Pharmaceuticals. It is being conducted within the Cystic Fibrosis Foundation’s Therapeutics Development Network.

Contact us about Fosfomycin/Tobramycin Inhalation Solution (FTI) >